124 related articles for article (PubMed ID: 11244324)
1. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.
Chi KH; Myers JN; Chow KC; Chan WK; Tsang YW; Chao Y; Yen SH; Lotze MT
Oncology; 2001; 60(2):110-5. PubMed ID: 11244324
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
3. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
8. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Atkins MB; Lotze MT; Dutcher JP; Fisher RI; Weiss G; Margolin K; Abrams J; Sznol M; Parkinson D; Hawkins M; Paradise C; Kunkel L; Rosenberg SA
J Clin Oncol; 1999 Jul; 17(7):2105-16. PubMed ID: 10561265
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
11. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
Geertsen PF; Hermann GG; von der Maase H; Steven K
J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
[TBL] [Abstract][Full Text] [Related]
12. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Kammula US; White DE; Rosenberg SA
Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
14. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
Atkins MB; Vachino G; Tilg HJ; Karp DD; Robert NJ; Kappler K; Mier JW
J Clin Oncol; 1992 Nov; 10(11):1802-9. PubMed ID: 1403061
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of carboplatin in nasopharyngeal carcinoma.
Chi KH; Chang YC; Chan WK; Liu JM; Law CK; Lo SS; Shu CH; Yen SH; Whang-Peng J; Chen KY
Oncology; 1997; 54(3):203-7. PubMed ID: 9143400
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
20. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.
Punt KC; Jansen RL; De Mulder PH; Batchelor D; Galazka A; Bolhuis RL; Stoter G
J Immunother (1991); 1992 Nov; 12(4):277-84. PubMed ID: 1477079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]